IDEXX LaboratoriesIDXX

IDEXX has acquired CoVetAI, a firm that specializes in using artificial intelligence for animal health. This move fits into the company's strategy of owning the software that veterinary clinics use to run their daily operations.

By folding AI tools into its existing platform, IDEXX makes its software more useful for vets, which helps keep them from switching to rivals. This integration is a key part of the business, as it ensures clinics continue to buy the high-margin testing kits and services that make up most of the company's revenue.

Source: PRNewsWire

IDEXX is adding a new test for taeniid tapeworms to its diagnostic platform in the United Kingdom. This expansion allows veterinarians to screen for a wider range of intestinal parasites using the company's existing antigen testing technology.

This move fits into the company's strategy of growing its international business by offering more specialized tests. Because IDEXX earns most of its money from the recurring sale of these testing kits, adding more types of detectable parasites helps ensure that clinics keep using its equipment for routine pet checkups.

Source: Business Wire

IDEXX has acquired CoVetAI, a company that uses artificial intelligence to help veterinary clinics manage their workflows. The goal is to integrate these tools into the software vets already use to run their practices, making it easier for them to handle things like patient notes and records.

This move fits into the company's strategy of becoming the essential operating system for pet clinics. By adding AI that saves vets time on paperwork, IDEXX makes its software more valuable and harder for clinics to stop using. This deepens the connection between the clinic and IDEXX's core business of selling diagnostic tests.

Source: Business Wire

Barclays lowered its price target for the company from $800 to $710. Even with the lower target, the firm kept its overweight rating, which is a signal that they still expect the stock to perform better than the broader market. This new target is still well above the current price of about $552. It is also higher than the average target across all analysts, which currently sits at $665. While the lower number reflects a more cautious view on the stock's price, the firm's outlook on the business itself remains positive.

Source: Barclays

The company launched the Catalyst proBNP Test, which allows veterinarians to screen both cats and dogs for heart disease directly in the clinic. Previously, these types of tests often required sending samples to an outside laboratory and waiting for results. This is the first test of its kind that can handle two different species on a single in-clinic machine.

This launch is a textbook example of how the company grows. By adding more types of tests to the machines it has already sold to clinics, it earns more recurring revenue from every pet visit. Because these machines are already integrated into the software vets use to run their practices, adding a new test like this makes the entire system more valuable and harder for a clinic to replace with a rival's equipment.

Source: Business Wire

Metrics we are tracking